Back to Search
Start Over
Comparison of sirolimus eluting stent with bioresorbable polymer to everolimus eluting stent with permanent polymer in bifurcation lesions: Results from CENTURY II trial
- Source :
- Catheterization and Cardiovascular Interventions. 87:1092-1100
- Publication Year :
- 2015
- Publisher :
- Wiley, 2015.
-
Abstract
- Objective To demonstrate the safety and efficacy of a new sirolimus eluting stent with bioresorbable polymer, Ultimaster, (BP-SES) compared with everolimus-eluting, permanent polymer, Xience stent (PP-EES) in bifurcation lesions with respect to the freedom from Target Lesion Failure at 1-year. Methods Within 1,119 patients enrolled in the CENTURY II randomized controlled multicenter trial, 194 patients were treated for bifurcation lesions and randomized to either BP-SES (n = 95) or PP-EES (n = 99). The primary endpoint was freedom from target lesion failure (TLF) composite endpoint [cardiac death, MI not clearly attributable to a non-target vessel, and clinically driven target lesion revascularization (TLR)] at 1-year. Results Baseline patient demographic, angiographic, and stenting characteristics were similar in both study arms. A single stent technique with provisional or “cross over” stenting were the most widely used in both arms (93.2% BP-SES vs. 92.4% PP-EES). Freedom from TLF at 1-year was 94.7% for BP-SES and 91.9% for PP-EES (P for noninferiority 0.031). The rate of clinically driven target lesion revascularization (TLR) at 1-year was 3.2% for BP-SES and 3.0% for PP-EES (P = 0.95). There were no significant differences detected in any of the individual clinical endpoints or other secondary clinical endpoints between the study arms at 1-year follow up. Conclusions The new bioresorbable polymer sirolimus-eluting stent showed safety and efficacy profiles similar to durable polymer everolimus-eluting in the treatment of patients with bifurcation lesions at 1-year follow up. © 2015 Wiley Periodicals, Inc.
- Subjects :
- Target lesion
medicine.medical_specialty
business.industry
Everolimus eluting stent
medicine.medical_treatment
Bioresorbable polymers
Stent
General Medicine
030204 cardiovascular system & hematology
Surgery
03 medical and health sciences
0302 clinical medicine
Drug-eluting stent
Multicenter trial
Sirolimus
Clinical endpoint
Medicine
Radiology, Nuclear Medicine and imaging
030212 general & internal medicine
Cardiology and Cardiovascular Medicine
business
medicine.drug
Subjects
Details
- ISSN :
- 15221946
- Volume :
- 87
- Database :
- OpenAIRE
- Journal :
- Catheterization and Cardiovascular Interventions
- Accession number :
- edsair.doi...........b94781a09a4cfbf5ee6f5901222bb0cc
- Full Text :
- https://doi.org/10.1002/ccd.26150